...
首页> 外文期刊>Biochimica et biophysica acta. Reviews on cancer >Super-enhancers: A new frontier for glioma treatment
【24h】

Super-enhancers: A new frontier for glioma treatment

机译:超级增强剂:一种新的胶质瘤治疗前沿

获取原文
获取原文并翻译 | 示例
           

摘要

Glioma is the most common primary malignant tumor in the human brain. Although there are a variety of treatments, such as surgery, radiation and chemotherapy, glioma is still an incurable disease. Super-enhancers (SEs) are implicated in the control of tumor cell identity, and they promote oncogenic transcription, which supports tumor cells. Inhibition of the SE complex, which is required for the assembly and maintenance of SEs, may repress oncogenic transcription and impede tumor growth. In this review, we discuss the unique characteristics of SEs compared to typical enhancers, and we summarize the recent advances in the understanding of their properties and biological role in gene regulation. Additionally, we highlight that SE-driven lncRNAs, miRNAs and genes are involved in the malignant phenotype of glioma. Most importantly, the application of SE inhibitors in different cancer subtypes has introduced new directions in glioma treatment.
机译:胶质瘤是人脑中最常见的原发性恶性肿瘤。 虽然有各种治疗方法,如手术,辐射和化疗,胶质瘤仍然是一种可治区疾病。 超级增强剂(SES)涉及对肿瘤细胞同一性的控制,并且它们促进致癌转录,其支持肿瘤细胞。 SES组装和维持所需的SE复合物的抑制可以抑制致癌转录并阻碍肿瘤生长。 在本次审查中,与典型的增强剂相比,我们讨论了SES的独特特征,我们总结了最近在基因调控中了解其性质和生物学作用的最新进展。 此外,我们突出显示SE驱动的LNCRNA,miRNA和基因涉及神经胶质瘤的恶性表型。 最重要的是,在不同癌症亚型中的Se抑制剂在胶质瘤治疗中引入了新的方向。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号